Inhibition of CoA-independent transacylase reduces inflammatory lipid mediators.
Winkler
J D
JD
Department of Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA.
Fonteh
A N
AN
Sung
C M
CM
Huang
L
L
Chabot-Fletcher
M
M
Marshall
L A
LA
Chilton
F H
FH
D000217:Acyltransferases / Q000037:antagonists & inhibitors*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001792:Blood Platelets / Q000201:enzymology*; D006801:Humans; D006918:Hydroxyurea / Q000031:analogs & derivatives* / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology*; D007249:Inflammation / Q000503:physiopathology*; D008407:Mast Cells / Q000201:enzymology*; D009000:Monocytes / Q000201:enzymology*; D009504:Neutrophils / Q000201:enzymology*; D009943:Organophosphorus Compounds / Q000494:pharmacology*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007093:Imidazoles; D009943:Organophosphorus Compounds; C093303:SK&F 98625; D000217:Acyltransferases; C039766:arachidonyl transacylase; C063449:zileuton; D006918:Hydroxyurea